BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9640970)

  • 1. Immunohistochemical status of p53, mdm2 and Ki-67 in malignant fibrous histiocytoma.
    Szadowska A; Olborski B; Harezga-Bal B; Debiec-Rychter M
    Pol J Pathol; 1998; 49(1):15-21. PubMed ID: 9640970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
    Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
    Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years.
    Kawaguchi K; Oda Y; Sakamoto A; Saito T; Tamiya S; Iwamoto Y; Tsuneyoshi M
    Mod Pathol; 2002 Aug; 15(8):878-88. PubMed ID: 12181274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of P53, MDM2 and Ki-67 antigens in soft tissue sarcomas.
    Szadowska A; Olborski B; Harezga-Bal B; Debiec-Rychter M
    Pol J Pathol; 1999; 50(1):9-16. PubMed ID: 10412269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retroperitoneal liposarcoma with combined well-differentiated and myxoid malignant fibrous histiocytoma-like myxoid areas.
    Hisaoka M; Morimitsu Y; Hashimoto H; Ishida T; Mukai H; Satoh H; Motoi T; Machinami R
    Am J Surg Pathol; 1999 Dec; 23(12):1480-92. PubMed ID: 10584701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
    Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E
    Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of p53 and mdm2 proteins in malignant fibrous histiocytoma in absence of gene alteration: prognostic significance.
    Molina P; Pellín A; Navarro S; Boix J; Carda C; Llombart-Bosch A
    Virchows Arch; 1999 Dec; 435(6):596-605. PubMed ID: 10628802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic implication of the p53 protein and Ki-67 antigen immunohistochemistry in malignant fibrous histiocytoma.
    Yang P; Hirose T; Hasegawa T; Seki K; Sano T; Hizawa K
    Cancer; 1995 Aug; 76(4):618-25. PubMed ID: 8625155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histiocyte-like cells expressing factor XIIIa do not belong to the neoplastic cell population in malignant fibrous histiocytoma.
    Szollosi Z; Nemeth T; Egervari K; Nemes Z
    Pathol Res Pract; 2005; 201(5):369-77. PubMed ID: 16047946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
    Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
    Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of p53, p21, mdm2, Rb, bax and Ki67 proteins in lymphomas of the mucosa-associated lymphoid (MALT) tissue.
    Stefanaki K; Tzardi M; Kouvidou C; Chaniotis V; Bolioti M; Vlychou M; Zois M; Kakolyris S; Delides G; Rontogianni D; Georgoulias V; Kanavaros P
    Anticancer Res; 1998; 18(4A):2403-8. PubMed ID: 9703886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
    Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
    J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential diagnosis of atypical epithelium of biopsied gastric mucosa using immunostaining of Ki-67, p53, hMLH1 and MDM2 expression.
    Ito E; Saito K; Takizawa T; Koike M
    J Exp Clin Cancer Res; 2002 Dec; 21(4):527-37. PubMed ID: 12636099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity.
    Coindre JM; Hostein I; Maire G; Derré J; Guillou L; Leroux A; Ghnassia JP; Collin F; Pedeutour F; Aurias A
    J Pathol; 2004 Jul; 203(3):822-30. PubMed ID: 15221942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of minichromosome maintenance-2 in human malignant fibrous histiocytomas: Correlations with Ki-67 and P53 expression, and apoptosis.
    Osaki M; Osaki M; Yamashita H; Shomori K; Yoshida H; Ito H
    Int J Mol Med; 2002 Aug; 10(2):161-8. PubMed ID: 12119552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders.
    Kanavaros P; Stefanaki K; Rontogianni D; Darivianaki K; Vlychou M; Papadaki E; Eliopoulos G; Bakiri M; Matsouka C; Kakolyris S; Georgoulias V
    Clin Exp Pathol; 1999; 47(5):231-8. PubMed ID: 10598372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis.
    Shiina H; Igawa M; Shigeno K; Yamasaki Y; Urakami S; Yoneda T; Wada Y; Honda S; Nagasaki M
    Oncology; 1999 Apr; 56(3):239-47. PubMed ID: 10202280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity.
    Bar JK; Grelewski P; Popiela A; Noga L; Rabczyñski J
    Gynecol Oncol; 2004 Oct; 95(1):23-31. PubMed ID: 15385106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53/MDM-2 immunohistochemical expression correlated with proliferative activity in different subtypes of human sarcomas: a ten-year follow-up study.
    Stefanou DG; Nonni AV; Agnantis NJ; Athanassiadou SE; Briassoulis E; Pavlidis N
    Anticancer Res; 1998; 18(6B):4673-81. PubMed ID: 9891539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical expression of p53, MDM2, Ki-67 and PCNA in central giant cell granuloma and giant cell tumor.
    de Souza PE; Paim JF; Carvalhais JN; Gomez RS
    J Oral Pathol Med; 1999 Feb; 28(2):54-8. PubMed ID: 9950250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.